Precision BioSciences (DTIL) financial statements
Precision BioSciences reported revenue of $34M in fiscal 2025, up 17.8% a year over 7 years.
Net income was -$46M and the operating margin -152.2%, against -440.2% in 2018.
Free cash flow was -$66M.
The diluted share count rose 2339% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Precision BioSciences's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11M | $22M | $24M | $116M | $25M | $49M | $69M | $34M |
| Research and development | $45M | $82M | $98M | $115M | $46M | $53M | $60M | $54M |
| Selling, general and admin | $14M | $27M | $36M | $40M | $41M | $39M | $35M | $32M |
| Operating income | -$48M | -$87M | -$110M | -$39M | -$62M | -$44M | -$26M | -$52M |
| Interest expense | — | $182,000 | — | $132,000 | $1M | $2M | $2M | $1M |
| Pre-tax income | — | — | — | — | — | — | $7M | -$46M |
| Income tax | — | — | $23,000 | — | — | — | $0 | $0 |
| Net income | -$46M | -$93M | -$109M | -$31M | -$112M | -$61M | $7M | -$46M |
| EPS (diluted) | -$87.60 | -$66.30 | -$62.70 | -$15.60 | -$38.10 | -$15.96 | $1.04 | -$3.56 |
| Diluted shares | 1M | 1M | 2M | 2M | 3M | 4M | 7M | 13M |
| Operating margin | -440.2% | -392.1% | -452.2% | -34.1% | -248.3% | -89.8% | -38.1% | -152.2% |
| Net margin | -423.0% | -417.6% | -448.9% | -26.5% | -444.8% | -125.8% | 10.4% | -133.4% |
Balance sheet
Fiscal years, from Precision BioSciences's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $103M | $181M | $90M | $144M | $190M | $117M | $86M | $116M |
| Receivables | $523,000 | $965,000 | $10M | $488,000 | $720,000 | $901,000 | $229,000 | $0 |
| Total current assets | $116M | $194M | $106M | $162M | $199M | $136M | $95M | $119M |
| Property, plant and equipment | $21M | $40M | $35M | $25M | $12M | $6M | $3M | $1M |
| Total assets | $139M | $235M | $150M | $211M | $238M | $160M | $136M | $154M |
| Total current liabilities | $14M | $27M | $43M | $36M | $60M | $50M | $15M | $9M |
| Total liabilities | $99M | $97M | $106M | $120M | $178M | $141M | $80M | $62M |
| Shareholders' equity | $40M | $138M | $44M | $91M | $60M | $19M | $56M | $92M |
| Net debt | -$103M | -$181M | -$90M | -$144M | -$190M | -$117M | -$86M | -$111M |
Cash flow
Fiscal years, from Precision BioSciences's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$52M | -$71M | -$87M | -$11M | -$46M | -$84M | -$58M | -$66M |
| Capital spending | $14M | $25M | $5M | $5M | $3M | $2M | $250,000 | $85,000 |
| Free cash flow | -$66M | -$96M | -$92M | -$16M | -$49M | -$86M | -$59M | -$66M |
| Stock-based compensation | $2M | $9M | $14M | $17M | $19M | $14M | $13M | $10M |
| Net borrowing | — | — | — | -$2M | — | — | — | — |
| Free cash flow margin | -606.5% | -430.3% | -380.6% | -13.8% | -195.5% | -176.6% | -85.4% | -192.4% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for DTIL.
Open DTIL in InvestinglyQuestions
What was Precision BioSciences's revenue in 2025?
$34M in fiscal 2025, from its 10-K filing.
How much free cash flow does Precision BioSciences generate?
-$66M in fiscal 2025 (operating cash flow minus capital spending).
From Precision BioSciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.